195 related articles for article (PubMed ID: 12796525)
21. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
[TBL] [Abstract][Full Text] [Related]
22. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Cai XY; Kong XM; Fang Q; Ning P; Xu YJ; Zhang B; Xue SR
Neurodegener Dis; 2012; 9(1):11-7. PubMed ID: 21876323
[TBL] [Abstract][Full Text] [Related]
23. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.
Kelada SN; Costa-Mallen P; Checkoway H; Carlson CS; Weller TS; Swanson PD; Franklin GM; Longstreth WT; Afsharinejad Z; Costa LG
Pharmacogenet Genomics; 2005 Sep; 15(9):659-68. PubMed ID: 16041244
[TBL] [Abstract][Full Text] [Related]
24. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
Rieck M; Schumacher-Schuh AF; Altmann V; Callegari-Jacques SM; Rieder CRM; Hutz MH
Pharmacogenomics J; 2018 Jan; 18(1):196-200. PubMed ID: 27779245
[TBL] [Abstract][Full Text] [Related]
25. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
[TBL] [Abstract][Full Text] [Related]
26. [Association between dopamine transporter gene polymorphism and Parkinson's disease].
Zhang L; Shao M; Xu Q; Dong X; Yang J; Li Y; Chen B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Dec; 18(6):431-4. PubMed ID: 11774209
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Comi C; Ferrari M; Marino F; Magistrelli L; Cantello R; Riboldazzi G; Bianchi ML; Bono G; Cosentino M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125015
[TBL] [Abstract][Full Text] [Related]
28. Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
Kusters CDJ; Paul KC; Guella I; Bronstein JM; Sinsheimer JS; Farrer MJ; Ritz BR
Parkinsonism Relat Disord; 2018 Feb; 47():39-44. PubMed ID: 29191473
[TBL] [Abstract][Full Text] [Related]
29. Variability and validity of polymorphism association studies in Parkinson's disease.
Tan EK; Khajavi M; Thornby JI; Nagamitsu S; Jankovic J; Ashizawa T
Neurology; 2000 Aug; 55(4):533-8. PubMed ID: 10953187
[TBL] [Abstract][Full Text] [Related]
30. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
Wedekind S
MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
[No Abstract] [Full Text] [Related]
31. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
[No Abstract] [Full Text] [Related]
32. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele.
Planté-Bordeneuve V; Taussig D; Thomas F; Said G; Wood NW; Marsden CD; Harding AE
Neurology; 1997 Jun; 48(6):1589-93. PubMed ID: 9191771
[TBL] [Abstract][Full Text] [Related]
34. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
36. Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5.
Kustanovich V; Ishii J; Crawford L; Yang M; McGough JJ; McCracken JT; Smalley SL; Nelson SF
Mol Psychiatry; 2004 Jul; 9(7):711-7. PubMed ID: 14699430
[TBL] [Abstract][Full Text] [Related]
37. Family-based association study between bipolar disorder and DRD2, DRD4, DAT, and SERT in Sardinia.
Bocchetta A; Piccardi MP; Palmas MA; Chillotti C; Oi A; Del Zompo M
Am J Med Genet; 1999 Oct; 88(5):522-6. PubMed ID: 10490710
[TBL] [Abstract][Full Text] [Related]
38. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
[TBL] [Abstract][Full Text] [Related]
39. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease.
Wang J; Zhao C; Chen B; Liu ZL
Neurosci Lett; 2004 Jan; 355(3):193-6. PubMed ID: 14732464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
